Hematology · Investigational
Thrombopoietin (TPO)
No lawful US pathway
01 · Overview
Thrombopoietin is the endogenous glycoprotein hormone and principal physiologic regulator of megakaryocyte development and platelet production. It acts through the thrombopoietin receptor, also called c-Mpl, on megakaryocyte progenitors and megakaryocytes to drive their proliferation, differentiation and platelet release.
Two recombinant versions were developed clinically, full-length recombinant human thrombopoietin and a truncated pegylated form, pegylated recombinant human megakaryocyte growth and development factor (PMID 20620436). No thrombopoietin product appears in the FDA drug approval database.
02 · Research summary & key findings
Both first-generation recombinant thrombopoietins showed significant biologic activity in clinical settings including non-myeloablative chemotherapy, progenitor mobilization and platelet apheresis, but their development was discontinued because neutralizing antibodies arose with the pegylated form (PMID 20620436). That experience led directly to second-generation thrombopoietin receptor agonists with no sequence homology to native thrombopoietin, such as romiplostim and eltrombopag, which activate the receptor without provoking cross-reactive antibodies (PMID 20620436). Eltrombopag was subsequently approved by the FDA in 2008 according to the FDA drug approval database.
03 · Regulatory status
Thrombopoietin (TPO) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Thrombopoietin (TPO) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 5 FDA-approved compounds in Hematology
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Subcutaneous injection
- Intravenous
References
- [1]Clinical findings with the first generation of thrombopoietic agents Semin Hematol, 2010. PMID 20620436
Primary literature
- PubMed: "Thrombopoietin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Thrombopoietin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Thrombopoietin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hematology
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.